Examining the Cardioprotective Benefits of Urate-Lowering Therapy in Gout
The authors reviewed the effects of urate-lowering therapy on cardiovascular disease in patients with gout.
The authors reviewed the effects of urate-lowering therapy on cardiovascular disease in patients with gout.
As previous studies indicated that all-cause hospitalizations in patients with gout in the United States have overwhelmingly increased by 410% in the last 22 years, researchers sought to determine the potential reasons for the excess hospitalizations.
Rates of serum creatinine events were higher among patients treated with both lesinurad and a xanthine oxidase inhibitor.
Investigators evaluated the prevalence, distribution, and factors associated with bone erosion detectable by ultrasound in patients with gout.